Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $185,994.26 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now directly owns 21,476 shares of the company’s stock, valued at $292,288.36. The trade was a 38.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Friday, December 6th, Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.78, for a total value of $123,914.88.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $12.06 on Friday. The stock has a market cap of $638.82 million, a price-to-earnings ratio of -5.74 and a beta of 0.95. The firm has a 50 day simple moving average of $12.49 and a 200-day simple moving average of $13.65. Stoke Therapeutics, Inc. has a 1-year low of $4.09 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Equities analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of STOK. Quest Partners LLC purchased a new position in Stoke Therapeutics during the second quarter worth about $29,000. Nisa Investment Advisors LLC boosted its position in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $123,000. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics in the third quarter valued at approximately $160,000. Finally, The Manufacturers Life Insurance Company raised its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on STOK. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.